Patents by Inventor Michael Mitas

Michael Mitas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110201012
    Abstract: Provided is a method for detecting metastases of epithelial cancers, comprising detecting in non-primary tissue overexpression of a nucleic acid of KS1/4, or detecting in non-primary tissue overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx, the overexpression of a nucleic acid of KS1/4, or the overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx in non-primary tissue being correlated with metastases of epithelial cancers.
    Type: Application
    Filed: October 19, 2010
    Publication date: August 18, 2011
    Inventors: MICHAEL MITAS, David J. Cole, William E. Gillanders, Michael Wallace
  • Patent number: 7981616
    Abstract: The present invention provides truncated gene-specific primers in panels that can be used during the reverse transcription step of RT-PCR to increase signal detection of cancer gene markers in a tissue sample. Also provided are forward and reverse primers for RT-PCR. Methods of using the primers are also provided.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: July 19, 2011
    Assignee: MUSC Foundation for Research Development
    Inventors: Michael Mitas, David J. Cole, William E. Gillanders, Kaidi Mikhitarian
  • Patent number: 7824857
    Abstract: Provided is a method for detecting metastases of epithelial cancers, comprising detecting in non-primary tissue overexpression of a nucleic acid of KS1/4, or detecting in non-primary tissue overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx, the overexpression of a nucleic acid of KS1/4, or the overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx in non-primary tissue being correlated with metastases of epithelial cancers.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: November 2, 2010
    Assignee: MUSC Foundation for Research Development
    Inventors: Michael Mitas, David J. Cole, William E. Gillanders, Michael Wallace
  • Publication number: 20080241849
    Abstract: Provided is a method for detecting metastases of epithelial cancers, comprising detecting in non-primary tissue overexpression of a nucleic acid of KS1/4, or detecting in non-primary tissue overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx, the overexpression of a nucleic acid of KS1/4, or the overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx in non-primary tissue being correlated with metastases of epithelial cancers.
    Type: Application
    Filed: May 13, 2008
    Publication date: October 2, 2008
    Inventors: Michael Mitas, David J. Cole, William E. Gillanders, Michael Wallace
  • Publication number: 20080233563
    Abstract: The present invention provides truncated gene-specific primers in panels that can be used during the reverse transcription step of RT-PCR to increase signal detection of cancer gene markers in a tissue sample. Also provided are forward and reverse primers for RT-PCR. Methods of using the primers are also provided.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 25, 2008
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Michael Mitas, David J. Cole, William E. Gillanders, Kaidi Mikhitarian
  • Publication number: 20080026481
    Abstract: Provided is a method of identifying a subject at risk of recurrence of adenocarcinoma, comprising detecting markers associated with recurrence. Provided is a method of identifying a subject at risk for recurrence of adenocarcinoma, comprising determining the ratio of EpCAM2 to CK19 in primary adenocarcinoma tissue from the subject, a high ratio of EpCAM2 to CK19 M indicating a subject at risk for recurrence. Also provided is method of identifying a subject at risk for recurrence of adenocarcinoma, comprising determining the ratio of CK19 and P-cadherin in primary adenocarcinoma tissue from the subject, a low ratio of CK19 to P-cadherin indicating a subject at risk for recurrence. A method of identifying a subject at risk for recurrence of adenocarcinoma is provided, comprising determining the ratio of Map7 to EpCAM2 in primary adenocarcinoma tissue from the subject, a low ratio of Map7 to EpCAM2 indicating a subject at risk for recurrence.
    Type: Application
    Filed: June 18, 2007
    Publication date: January 31, 2008
    Inventor: Michael Mitas
  • Publication number: 20070231822
    Abstract: Methods are provided for the detection of and determining prognosis of metastatic breast, lung, prostate, and/or pancreatic cancer using various genetic markers, including markers for gene clusters linked by Esx. In one method, breast cancer micrometastases and non-small cell lung cancer metastases or micrometastases are detected in a patient by determining whether the AGR2 or TFF1 genes are overexpressed in a cell sample compared to control lymph node tissue cells. In a further method, the likelihood that a patient diagnosed with breast cancer will respond to hormonal therapy is predicted by determining a higher expression level of the AGR2 gene compared to a control gene. In a further method, a decreased probability of survival for a patient diagnosed with early stage non-small cell lung cancer is predicted by determining a higher expression level of the AGR2 gene compared to a control gene. Kits for practicing the methods of the invention are further provided.
    Type: Application
    Filed: February 27, 2007
    Publication date: October 4, 2007
    Inventor: Michael Mitas
  • Publication number: 20050123976
    Abstract: Provided is a method for detecting metastases of epithelial cancers, comprising detecting in non-primary tissue overexpression of a nucleic acid of KS1/4, or detecting in non-primary tissue overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx, the overexpression of a nucleic acid of KS1/4, or the overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx in non-primary tissue being correlated with metastases of epithelial cancers.
    Type: Application
    Filed: December 2, 2004
    Publication date: June 9, 2005
    Inventors: Michael Mitas, David Cole, William Gillanders, Michael Wallace